AliveDx (“Company”) is proud to announce it has received IVDR CE mark for its groundbreaking microarray immunoassay, designed for the detection of a specific IgE directed to a protein allergen in human serum. This is the Company’s first product for the evaluation of allergies, enhancing its portfolio of products beyond autoimmunity. This immunoassay, run on AliveDx’s proprietary MosaiQ® platform, is an important milestone for the current development of the Company’s multiplex immunoassay microarray, which aims...